Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 155

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 155
---
 and Permitted Deductions or any calculations with respect to the Additional Closing Net Cash Proceeds, as applicable.

Purchaser shall not, in whole or in part, assign any of its obligations under this Agreement other than in accordance with
the terms of .

During the Existing Partnership Period, Purchaser shall, and shall cause its Affiliates (including the Company (after the Closing)), and
licensees and rights transferees to, use commercially reasonable efforts to (i) maintain and enforce the Existing Partnership Agreements and (ii) comply in all material respects with their respective covenants and obligations under each
Existing Partnership Agreement.

F-14

During the Efforts Disposition Period, Purchaser shall, and shall cause its Affiliates
(including the Company (after the Closing)), licensees and rights transferees to, use commercially reasonable efforts to (i) enter into one or more Disposition Agreements as promptly as practicable following the Closing, (ii) maintain and
enforce any Disposition Agreements entered into prior to or following the Closing Date and (iii) retain an employee or consultant of Purchaser or the Company for the purpose of maintaining and preserving the CVR Products.

During the Efforts Disposition Period, Purchaser shall, and shall cause its Affiliates (including the Company (after the Closing)), and
licensees and rights transferees to, use commercially reasonable efforts to comply in all material respects with their respective covenants and obligations under each such Disposition Agreement.

During the Efforts Disposition Period, Purchaser shall, and shall cause its Affiliates (including the Company (after the Closing)), licensees
and rights transferees to, use commercially reasonable efforts to maintain and prosecute the intellectual property relating to the CVR Products. For the avoidance of doubt, Purchaser and (after the Closing) the Company are not obligated to pursue
new clinical, manufacturing or enabling work with respect to the CVR Products, except as otherwise required pursuant to the applicable Disposition Agreement, Existing Partnership Agreement, or agreement governing a Permitted Disposition.

During the Existing Partnership Period and the Disposition Period, Purchaser shall, and (after the Closing) shall cause the Company to
maintain the CVRs (including fees and expenses related to the Rights Agent and the Representative).

During the Disposition Period:
(i) Purchaser shall, and (after the Closing) shall cause the Company to, maintain records in the ordinary course of business pursuant to record-keeping procedures